Armen Panossian
Analyst · JPMorgan. Please go ahead
Yes. Good question. So in terms of size Finn, the market ebbs and flows. So late last year when the markets were pretty strong and wide open from a banking perspective, we saw spreads tightening in broadly syndicated loans, we saw spreads tightening in high yield bonds and we saw new issuance in senior loans, creation of CLOs and we saw a tightening in direct lending as well. And in the larger borrower segment we found that or the borrowers found that they could get better pricing and looser legal terms from the broadly syndicated loan market versus direct lending. So it was, I would say it felt a little bit more challenging or the trend did not feel so great for the ultra large cap, the $150 million plus EBITDA category for new deals what didn’t feel so great in the back half or the fourth quarter, fourth calendar quarter of last year. With some of the volatility we’ve been seeing in the markets though in the last month, month and a half, we are seeing a pullback in new issuance activity from the banks. And so we are seeing a return of some larger borrowers into the direct lending market post-Liberation Day. And so the pipeline from that perspective is, I would say on the margin better for issuing direct loans to very large borrowers. With that said, M&A deal volume is not as robust as we would like it to be overall as a market. Now the reason for that is in the fourth quarter after President Trump was elected, there was, I would say, some positive feelings about where the market would go and where rates would go? President Trump generally at that time was considered to be somebody who would lean on lower rates, would lean on deregulation, and those would be good things for deal flow and the transaction of sponsor-to-sponsor LBOs. Now, so there was a lot of activity, at least in terms of discussions, late last year and early this year as to, hey, 2025 issuance is going to be very strong and M&A volumes will be strong. But the tariff announcements have thrown a wrench in that. And it just seems like private equity sponsors generally are reticent to do deals pending, kind of what’s going to happen with these tariffs, because it leans on higher rates, it leans on more inflation, and all of that is sort of bad for valuation multiples. So there is a, I think somewhat of a pause happening right now in two respects. One is private equity sponsors doing new deals and two, corporate borrowers that have some level of tariff related exposure, i.e., that is part of their supply chain runs through a non-U.S. market or part of their sales go to a non-U.S. market. We’re seeing that there is a pause in building up of inventory, a pause in CapEx spending. And given that backdrop, I would expect to see continued sort of reservations around deal activity for a few months at least. So that’s kind of the current condition around deal flow, large cap, but the deals that are getting done so high quality businesses that are somewhat insulated from tariff impacts that are still being LBO’d. And there have been some announcements in the last few weeks. So deals are happening just at less of a rate. Those deals are getting done more frequently in the direct lending market rather than broadly syndicated loan market. So we are engaged in those situations. Our pipeline for the quarter so far for this quarter that we’re in so far is actually pretty good just given some of that pullback from the banks. So we feel good about that condition. To answer your second question about the markdowns, no, look the markdowns are not in large cap sponsored lendings – the markdowns, unfortunately, it’s been the same names for a few quarters now, for a couple of years now that have kind of weighed on performance and I don’t – there isn’t anything thematic about them. But other than mid last year with Pluralsight, which was a very large LBO that had some issues which I think we’ve discussed in the past and has been pretty well known in the market other than that one situation. The rest of them are sort of idiosyncratic situations where just businesses have not executed the way they should have. In the case of SiO2, a business that was doing incredibly well during COVID, took a lot of that profitability and spent it on new R&D that didn’t pan out unfortunately. And so that’s not really a large cap issue or a big versus small business issue. It’s a deal where the execution around that technology just did not meet expectations.
Finian O’Shea: Okay. Thank you.